In this study, the authors used SNU499, a lenvatinib-resistant HCC cell line, to carry out synthetic lethal CRISPR screens, and discovered the knockout of EGFR under lenvatinib treatment is lethal to EGFR-expressing HCC cells. Here, EGFR is linked to hepatocellular carcinoma.